Subscribe for unlimited access to DynaMed content, CME/CE & MOC credit, and email alerts on content you follow.

Already subscribed? Sign in now

CME

Age-related Macular Degeneration (AMD)

24 Apr 2020

drusen area within 3 mm of fovea and drusen reflectivity may be associated with conversion to neovascular AMD in fellow eye of adults with previously treated AMD (JAMA Ophthalmol 2019 Jul 1)

24 Apr 2020

drusen area within 3 mm of fovea and drusen reflectivity may be associated with conversion to neovascular AMD in fellow eye of adults with previously treated AMD (JAMA Ophthalmol 2019 Jul 1)

24 Apr 2020

genetic variant rs61941274 (ACAD10 locus) might be associated with conversion to neovascular AMD in fellow eye of adults with previously treated AMD (JAMA Ophthalmol 2019 Jul 1)

24 Apr 2020

genetic variant rs61941274 (ACAD10 locus) might be associated with conversion to neovascular AMD in fellow eye of adults with previously treated AMD (JAMA Ophthalmol 2019 Jul 1)

16 Oct 2019

brolucizumab-dbll (Beovu) intravitreal injection FDA approved for treatment of neovascular ("wet") age-related macular degeneration (FDA Label 2019 Oct)

16 Oct 2019

brolucizumab-dbll (Beovu) intravitreal injection FDA approved for treatment of neovascular ("wet") age-related macular degeneration (FDA Label 2019 Oct)

25 Jul 2019

vision improvements achieved after 1 year of fixed dosing of ranibizumab every 4 weeks or aflibercept every 4 or 8 weeks reported to be maintained after 44 weeks of switching to treatment as needed (Am J Ophthalmol 2019 Apr)

25 Jul 2019

vision improvements achieved after 1 year of fixed dosing of ranibizumab every 4 weeks or aflibercept every 4 or 8 weeks reported to be maintained after 44 weeks of switching to treatment as needed (Am J Ophthalmol 2019 Apr)

15 Jul 2019

subthreshold nanosecond laser may reduce progression to late AMD in adults with intermediate AMD without reticular pseudodrusen (Ophthalmology 2019 Jun)

15 Jul 2019

subthreshold nanosecond laser may reduce progression to late AMD in adults with intermediate AMD without reticular pseudodrusen (Ophthalmology 2019 Jun)

15 May 2019

treat-and-extend aflibercept reported to improve visual acuity by about 10 letters with need for rescue photodynamic therapy at 1 year in about 12% of patients with symptomatic macular polypoidal choroidal vasculopathy (JAMA Ophthalmol 2018 Jul 1)

15 May 2019

treat-and-extend aflibercept reported to improve visual acuity by about 10 letters with need for rescue photodynamic therapy at 1 year in about 12% of patients with symptomatic macular polypoidal choroidal vasculopathy (JAMA Ophthalmol 2018 Jul 1)

2 May 2019

treat-and-extend ranibizumab may slightly improve visual acuity and reduce number of injections compared to monthly injection schedule in adults with treatment-naive neovascular AMD (Ophthalmology 2019 Jan 21 early online)

2 May 2019

treat-and-extend ranibizumab may slightly improve visual acuity and reduce number of injections compared to monthly injection schedule in adults with treatment-naive neovascular AMD (Ophthalmology 2019 Jan 21 early online)

2 May 2019

bevacizumab and ranibizumab may be associated with similar improvement in visual acuity in patients with neovascular AMD (Cochrane Database Syst Rev 2019 Mar 4)

2 May 2019

bevacizumab and ranibizumab may be associated with similar improvement in visual acuity in patients with neovascular AMD (Cochrane Database Syst Rev 2019 Mar 4)

13 Mar 2019

in patients with neovascular AMD receiving treat-and-extend ranibizumab regimen, extending treatment interval after resolution of intraretinal fluid alone may reduce total number of treatments and result in similar visual acuity at 24 months compared to extending treatment interval after resolution of both intraretinal fluid and subretinal fluid (Ophthalmology 2018 Nov 29)

13 Mar 2019

in patients with neovascular AMD receiving treat-and-extend ranibizumab regimen, extending treatment interval after resolution of intraretinal fluid alone may reduce total number of treatments and result in similar visual acuity at 24 months compared to extending treatment interval after resolution of both intraretinal fluid and subretinal fluid (Ophthalmology 2018 Nov 29)

11 Feb 2019

intravitreal conbercept improves best-corrected visual acuity at 3 months in patients with choroidal neovascularization secondary to AMD (Am J Ophthalmol 2019 Jan)

11 Feb 2019

intravitreal conbercept improves best-corrected visual acuity at 3 months in patients with choroidal neovascularization secondary to AMD (Am J Ophthalmol 2019 Jan)

11 Feb 2019

treat-and-extend regimens of ranibizumab and aflibercept associated with similar improvement in visual acuity and require similar number of injections over 1 year in patients with active choroidal neovascularization secondary to neovascular AMD (JAMA Ophthalmol 2019 Jan 24)

11 Feb 2019

treat-and-extend regimens of ranibizumab and aflibercept associated with similar improvement in visual acuity and require similar number of injections over 1 year in patients with active choroidal neovascularization secondary to neovascular AMD (JAMA Ophthalmol 2019 Jan 24)

13 Jul 2018

prism spectacles do not appear to increase reading speed compared to conventional spectacles in patients with AMD, but some mouse-based and stand-mounted electronic devices may have benefit in patients with low vision (Cochrane Database Syst Rev 2018 Apr 17)

13 Jul 2018

prism spectacles do not appear to increase reading speed compared to conventional spectacles in patients with AMD, but some mouse-based and stand-mounted electronic devices may have benefit in patients with low vision (Cochrane Database Syst Rev 2018 Apr 17)

12 Jul 2018

artificial intelligence-based image analysis helps rule out referable age-related macular degeneration in patients with diabetes (JAMA 2017 Dec 12)

12 Jul 2018

artificial intelligence-based image analysis helps rule out referable age-related macular degeneration in patients with diabetes (JAMA 2017 Dec 12)

top

Subscribe for unlimited access to DynaMed content.
Already subscribed? Sign in